News and Trends 5 Sep 2022
First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib
The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]